interestingly COAST reports ph3 first in early Q2 2025 which is trial with eyelea - eyelea has $6B+ in sales and from memory OPT p2b in comparison to eyelea was better result than against lucentis (which only does about $1.5B of sales p.a)
So all in all - it’s the first trial result which will make or break this company
Ann: Security Class Reinstatement to Quotation- OPTOB, page-18
-
- There are more pages in this discussion • 248 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
82.5¢ |
Change
0.015(1.85%) |
Mkt cap ! $1.015B | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 84.5¢ | 80.0¢ | $2.835M | 3.473M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17359 | 82.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 83.0¢ | 106026 | 2 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |